Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Home
Hostname: page-component-ffbbcc459-8fjtn Total loading time: 0.204 Render date: 2022-03-11T12:47:30.915Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "useRatesEcommerce": false, "useNewApi": true }
  • English
CNS Spectrums CNS Spectrums

Article contents

Escitalopram: A Second-Generation SSRI

Published online by Cambridge University Press:  07 November 2014

Michael J. Owens  and
Jerrold F. Rosenbaum
Get access Rights & Permissions[Opens in a new window]

Abstract

Serotonin (5-hydroxytryptamine, 5-HT) has long been suspected to play a role in the etiology of depression, and modern neurochemical techniques have confirmed this suspicion. Furthermore, all drugs known to be selective (a relative term) serotonin transporter (SERT) inhibitors are effective antidepressants. Of the selective serotonin reuptake inhibitors (SSRIs) approved in a number of countries for use in depression, panic disorder, and obsessive-compulsive disorder, citalopram is the most selective. Citalopram has been used worldwide to treat an estimated 35 million patients, with an excellent safety record. Citalopram is a racemic drug, and its effects on serotonin transport are thought to reside in the S-enantiomer, known as (S)-citalopram or escitalopram. Escitalopram is the most selective SSRI yet developed. Its receptor binding properties and activity in preclinical animal models of depression predict that escitalopram would be effective in the treatment of depression, with approximately twice the potency of the racemate. The pivotal clinical trials of escitalopram not only support this conclusion, but also suggest escitalopram possesses advantages over citalopram in terms of both efficacy and safety. In conclusion, escitalopram is a promising candidate for use as a first-line antidepressant.

Type
Research Article
Information
CNS Spectrums , Volume 7 , Issue S1: The Biological and Clinical Significance of Single Isomers , April 2002 , pp. 34 - 39
Copyright
Copyright © Cambridge University Press 2002

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Kraepelin, E. Über die Beeinflussung einfacher psychischer Vorgänge durch einigeArzneimittel. Jena, Germany: Fischer; 1892.Google Scholar
2.Stanley, M, Virgilio, J, Geishon, S. Tritiated Imipramine binding sites are decreased in the frontal cortex of suicides. Science. 1982;216:1337–1339.CrossRefGoogle ScholarPubMed
3.Perry, EK, Marshall, EF, Blessed, G, Tomlinson, BE, Perry, RH. Decreased imipramine binding in the brains of patients with depressive illness. Br J Psychiatry. 1983;142:188–192.CrossRefGoogle ScholarPubMed
4.Owens, MJ, Nemeroff, CB. The serotonin transporter and depression. Depress Anxiety. 1998;8(suppl 1):5–12.3.0.CO;2-I>CrossRefGoogle ScholarPubMed
5.Lopez, JF, Chalmers, DT, Vázquez, DM, Watson, SJ, Akil, H. Serotonin transporter mRNA in rat brain is regulated by classical antidepressants. Biol Psychiatry. 1994;35:287–290.CrossRefGoogle ScholarPubMed
6.Owens, MJ, Nemeroff, CB. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clinical Chemistry. 1994;40:288–295.Google ScholarPubMed
7.Owens, MJ, Ritchie, JC. Clinical neuroehemistry. In: Charney, DS, EJ, Nestler, Bunney, BS, eds. Neurobiology of Mental Illness. New York, NY: Oxford University Press; 1999:132–148.Google Scholar
8.Ellis, PM, Salmond, C. Is platelet imipramine binding reduced in depression? A meta-analysis. Biol Psychiatry. 1994;36:292–299.CrossRefGoogle ScholarPubMed
9.Owens, MJ, Ballenger, CA, Knight, DL, Nemeroff, CB. Platelet 5-hydroxytryptamine (5-HT) transporter and 5-HT2A receptor binding after chronic hyper-corticosteronemia, (±)-1-(2,5-dimelhoxy-4-iodophenyl)-2-aminopropane administration or neurotoxin-induced depletion of central nervous system 5-HT in the rat. J Pharmacol Exp Ther. 1996;278:1040–1049.Google ScholarPubMed
10.Robertson, DW, Krushinski, JH, Fuller, RW, Leander, JD. Absolute configurations and pharmacological activities of the optical isomers of fluoxetine, a selective serotonin-uptake inhibitor. J Med Chem. 1988;31:1412–1417.CrossRefGoogle ScholarPubMed
11.Wong, DT, Threlkeld, PG, Robertson, DW. Affinities of fluoxetine, its enantiomers, and other inhibitors of serotonin uptake for subtypes of serotonin receptors. Neuropsychopharmacology. 1991;5:43–47.Google ScholarPubMed
12.Thayer, A. Eli Lilly pulls the plug on Prozac isomer drug. Chem Engin News. 2000;78:8.CrossRefGoogle Scholar
13.Hyttel, J, Bogeso, P, Perregaard, J, Sanchez, C. The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer. J Neural Tramm Gen Sect. 1992;88:157–160.CrossRefGoogle ScholarPubMed
14.Owens, MJ, Knight, BS, Nemeroff, CB. Second generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry. 2001;50:345–350.CrossRefGoogle ScholarPubMed
15.Willner, P. Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology. 1997;134:319–329.CrossRefGoogle ScholarPubMed
16.Montgomery, SA, Loft, H, Sanchez, C, Reines, EH, Papp, M. Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from rat model. Pharmacol Toxicol. 2001;88:282–286.CrossRefGoogle ScholarPubMed
17.Papp, M, Sanchez, C. Escitalopram: potent and rapid in chronic mild stress model of depression. Poster presented at: Annual Meeting of the New Clinical Drug Evaluation Unit; 05 2001; Phoenix, AZ.Google Scholar
18.Mitchell, PJ, Hogg, S. Behavioural effects of escitalopram predict potent antidepressant activity. Poster presented at: Annual Meeting of the Society of Biological Psychiatry; 05 3-5, 2001; New Orleans, LA.Google Scholar
19.Sanchez, C. Escitalopram has potent anxiolytic effects in rodent anxiety models. Poster presented at: Annual Meeting of the New Clinical Drug Evaluation Unit; 05 2001; Phoenix, AZGoogle Scholar
20.Von Moltke, LL, Greenblatt, DJ, Giancarlo, GM, Granda, BW, Hannatz, JS, Shader, RI. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-eitalopram. Drug Metab Dipos. 2001;29:1102–1109.Google Scholar
21.Burke, WJ, Gergel, I, Bose, A. Fixed dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry. 2002;63:in press.CrossRefGoogle ScholarPubMed
22.Burke, WJ. Fixed dose study of escitalopram in the treatment of depression. Poster presented at: Annual Meeting of the American Psychiatric Association; 05 5-10, 2001; New Orleans, LA.Google Scholar
23. Data on file, Forest Laboratories.Google Scholar
24.Rosen, RC, Lane, RM, Menza, M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol. 1999;19:67–85.CrossRefGoogle ScholarPubMed
14
Cited by

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Escitalopram: A Second-Generation SSRI
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

Escitalopram: A Second-Generation SSRI
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

Escitalopram: A Second-Generation SSRI
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *